HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2015 and provided the shareholders with an update regarding future developments in his speech "The right translation at Evotec". Furthermore, Enno Spillner, who will become Chief Financial Officer of Evotec AG effective 18 July 2016, was introduced.
At the Annual General Meeting 2016, the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2015 were approved. The Annual General Meeting also approved a new resolution authorising the issuance of convertible bonds and/or warrant-linked bonds, participation rights and/or income bonds and the creation of new contingent capital. Moreover, the Annual General Meeting passed the other agenda items requiring shareholders' approval, hereunder amendments to the Articles of Association and the appointment of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft, Hamburg, as the auditor for fiscal year 2016.
At the ordinary Annual General Meeting 2016 of Evotec AG, 36.34% of the voting capital was present.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with MedImmune and Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Second Genome in the field of inflammatory diseases. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX|